Archive · 11 Aug 2025
Cannabis Stocks Rally on Trump Reclassification Report
Imagine some companies grow and sell a plant called cannabis.
Right now, the US government treats it like a very dangerous drug, like heroin.
But there's a rumor that a top leader might change the rules, making cannabis less restricted.
This made the companies' stocks go up, meaning they became more valuable.
If this change happens, it could help the cannabis businesses by allowing for more research, making it easier to get money, and making people view them more positively.
However, the impact might not be immediate, especially for companies that don't operate in the US.
Cannabis stocks surged on Monday following a report that Trump is considering reclassifying marijuana.
Village Farms International Inc. saw a 42% jump, while Tilray, Canopy Growth, Aurora Cannabis, SNDL, and Cronos Group also rose.
The report cited Trump's remarks at a fundraising event regarding the potential reclassification.
Cannabis is currently a Schedule 1 drug, and reclassification could lead to a Schedule III status.
Analysts suggest reclassification may boost the sector through research, reduced stigma, and increased access to capital.
- Who
- Shares of cannabis-linked companies like Village Farms International Inc., Tilray Brands Inc., Canopy Growth Corp., Aurora Cannabis Inc., SNDL Inc., and Cronos Group Inc. increased.
- What
- Cannabis stocks rallied due to reports of potential marijuana reclassification.
- When
- Shares rose on Monday.
- Where
- United States
- Why
- Investors reacted to reports of a possible reclassification of marijuana by the Trump administration.
Pro-Reclassification
N/A
Sector impact
Pro-Reclassification
Reclassification will help boost the sector by allowing more research, increasing access to capital, and reducing negative views.
N/A
N/A
- Companies affected
- Village Farms International Inc., Tilray Brands Inc., Canopy Growth Corp., Aurora Cannabis Inc., SNDL Inc., Cronos Group Inc.
- Current Status
- Cannabis is a Schedule 1 drug.
- Potential New Status
- Schedule III drug
- ETF Performance
- Amplify Alternative Harvest ETF rose up to 20%
- Source of Report
- Wall Street Journal